Ja Kyung Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12304/publications.pdf

Version: 2024-02-01

		159573	155644
80	3,285	30	55
papers	citations	h-index	g-index
0.2	0.2	0.2	4757
83	83	83	4757
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone. Clinical Pharmacology in Drug Development, 2022, 11, 576-584.	1.6	1
2	IL-15 enhances CCR5-mediated migration of memory CD8+ TÂcells by upregulating CCR5 expression in the absence of TCR stimulation. Cell Reports, 2021, 36, 109438.	6.4	16
3	Risk assessment of hepatocellular carcinoma and liverâ€related events using ultrasonography and transient elastography in patients with chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1362-1372.	2.0	4
4	Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers, 2020, 12, 1612.	3.7	4
5	Is liver biopsy still useful in the era of non-invasive tests?. Clinical and Molecular Hepatology, 2020, 26, 302-304.	8.9	11
6	Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. Journal of Clinical Gastroenterology, 2018, 52, 557-562.	2.2	6
7	Selective deletion of hepatocyte platelet-derived growth factor receptor \hat{l}_{\pm} and development of liver fibrosis in mice. Cell Communication and Signaling, 2018, 16, 93.	6.5	17
8	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. Cell Transplantation, 2017, 26, 1059-1066.	2.5	15
9	Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Radiation Oncology, 2017, 12, 133.	2.7	2
10	Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of DaclatasvirÂ+ÂAsunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virology Journal, 2017, 14, 164.	3.4	5
11	Platelet-derived growth factor receptor \hat{l}_{\pm} in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget, 2017, 8, 39534-39546.	1.8	16
12	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. Journal of Korean Medical Science, 2016, 31, 1431.	2.5	7
13	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0157358.	2.5	62
14	Transplantation with autologous bone marrowâ€derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology, 2016, 64, 2185-2197.	7.3	213
15	A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats. Journal of Gene Medicine, 2016, 18, 16-26.	2.8	9
16	Clinicopathological features of choledocholithiasis patients with high aminotransferase levels without cholangitis. Medicine (United States), 2016, 95, e5176.	1.0	15
17	Effect of eicosapentaenoic acid on cholesterol gallstone formation in C57BL/6J mice. Molecular Medicine Reports, 2015, 11, 362-366.	2.4	6
18	Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. Gut, 2015, 64, 1303-1313.	12.1	38

#	Article	IF	Citations
19	Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis. European Journal of Internal Medicine, 2015, 26, 292-296.	2.2	4
20	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. Gut and Liver, 2015, 9, 405-10.	2.9	10
21	Assessment of Hepatic Fibrosis Regression by Transient Elastography in Patients with Chronic Hepatitis B Treated with Oral Antiviral Agents. Journal of Korean Medical Science, 2014, 29, 570.	2.5	15
22	Concurrent Chemoradiotherapy Shows Long-Term Survival after Conversion from Locally Advanced to Resectable Hepatocellular Carcinoma. Yonsei Medical Journal, 2014, 55, 1489.	2.2	18
23	Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Experimental and Molecular Medicine, 2014, 46, e127-e127.	7.7	23
24	Individual prediction model for lamivudine treatment response in hepatitis <scp>B</scp> virus e antigenâ€positive chronic hepatitis <scp>B</scp> patients. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1049-1055.	2.8	6
25	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as firstâ€line therapy: A <scp>K</scp> orean multicenter study. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1463-1469.	2.8	26
26	Impact of postoperative hepatitis $\langle scp \rangle B \langle scp \rangle$ virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1019-1027.	2.8	12
27	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clinical and Experimental Metastasis, 2014, 31, 475-482.	3.3	26
28	Hepatitis C Virus Attenuates Interferon-Induced Major Histocompatibility Complex Class I Expression and Decreases CD8+ TÂCell Effector Functions. Gastroenterology, 2014, 146, 1351-1360.e4.	1.3	31
29	Longâ€ŧerm outcomes of chronic hepatitis <scp>B</scp> virus infection in the era of antiviral therapy in <scp>K</scp> orea. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1005-1011.	2.8	16
30	Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of kruppel-like-factor 10 in mice. Journal of Translational Medicine, 2014, 12, 186.	4.4	22
31	A pilot study of autologous CD34-depleted bone marrow mononuclear cell transplantation via the hepatic artery in five patients with liver failure. Cytotherapy, 2013, 15, 1571-1579.	0.7	21
32	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. Journal of Clinical Gastroenterology, 2013, 47, 538-544.	2.2	42
33	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. Clinical and Molecular Hepatology, 2013, 19, 29.	8.9	13
34	Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clinical and Molecular Hepatology, 2013, 19, 165.	8.9	26
35	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. Gut and Liver, 2013, 7, 329-334.	2.9	12
36	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. Intervirology, 2012, 55, 112-118.	2.8	11

#	Article	lF	Citations
37	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion, 2012, 86, 264-272.	2.3	2
38	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. European Journal of Gastroenterology and Hepatology, 2012, 24, 849-856.	1.6	35
39	Nâ€3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1745-1751.	2.8	22
40	CD11b ⁺ Gr1 ⁺ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology, 2012, 56, 1902-1912.	7.3	65
41	The significance of ICGâ€R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver International, 2012, 32, 1165-1171.	3.9	19
42	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. Scandinavian Journal of Infectious Diseases, 2012, 44, 144-148.	1.5	4
43	Discordance between Liver Biopsy and FibroScan \hat{A}^{\otimes} in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation. PLoS ONE, 2012, 7, e32233.	2.5	49
44	A Case of Acute Disseminated Encephalomyelitis Associated with Hepatitis C Virus Infection. Yonsei Medical Journal, 2012, 53, 856.	2.2	15
45	Transitional features of histologic type of nonâ€alcoholic fatty liver disease in Korean young men. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 142-148.	2.8	4
46	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Experimental and Molecular Medicine, 2011, 43, 341.	7.7	36
47	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antiviral Therapy, 2011, 16, 469-477.	1.0	20
48	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 171-178.	2.8	42
49	Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver International, 2011, 31, 369-376.	3.9	55
50	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 659-667.	2.5	57
51	¹⁸ Fâ€fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer, 2011, 117, 4779-4787.	4.1	47
52	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. American Journal of Gastroenterology, 2011, 106, 1654-1662.	0.4	56
53	Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. Cell Transplantation, 2010, 19, 1237-1246.	2.5	84
54	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. Journal of Clinical Gastroenterology, 2010, 44, 66-71.	2.2	94

#	Article	IF	Citations
55	Association Between Polymorphism of Tumor Necrosis Factor-α Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2010, 55, 2043-2048.	2.3	7
56	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. Digestive Diseases and Sciences, 2010, 55, 2636-2643.	2.3	7
57	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver International, 2010, 30, 546-553.	3.9	225
58	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver International, 2010, 30, 860-866.	3.9	16
59	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. Liver International, 2010, 30, 1073-1081.	3.9	31
60	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. Journal of Korean Medical Science, 2010, 25, 882.	2.5	15
61	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. American Journal of Gastroenterology, 2010, 105, 1382-1390.	0.4	194
62	Reactivation of Hepatitis B Viral Infection in Inactive HBsAg Carriers Following Anti-Tumor Necrosis Factor-α Therapy. Journal of Rheumatology, 2009, 36, 2416-2420.	2.0	109
63	Hepatitis B e antigenâ€negative mutations in the precore and core promoter regions in Korean patients. Journal of Medical Virology, 2009, 81, 594-601.	5.0	19
64	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. Journal of Medical Virology, 2009, 81, 1002-1008.	5.0	50
65	Variability in liver stiffness values from different intercostal spaces. Liver International, 2009, 29, 760-766.	3.9	19
66	Recombinant Interferon-Beta-1a Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study. Gut and Liver, 2009, 3, 20-25.	2.9	5
67	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. Antiviral Therapy, 2009, 14, 705-712.	1.0	26
68	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver International, 2008, 28, 393-401.	3.9	113
69	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer, 2008, 113, 995-1003.	4.1	138
70	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 2008, 29, 1192-1196.	2.8	119
71	Role of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in Detecting Extrahepatic Metastasis in Pretreatment Staging of Hepatocellular Carcinoma. Oncology, 2007, 72, 104-110.	1.9	101
72	Changes in Serum and Ascitic Monocyte Chemotactic Protein-1 (MCP-1) and IL-10 Levels in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Journal of Interferon and Cytokine Research, 2007, 27, 227-230.	1.2	32

#	Article	IF	CITATION
73	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. European Journal of Gastroenterology and Hepatology, 2007, 19, 923-926.	1.6	16
74	PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. Oncology, 2007, 72, 52-57.	1.9	91
7 5	Repetitive shortâ€course hepatic arterial infusion chemotherapy with highâ€dose 5â€fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer, 2007, 110, 129-137.	4.1	102
76	Liver cancer in Korea. Hepatology Research, 2007, 37, S106-S109.	3.4	18
77	Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clinical Cancer Research, 2006, 12, 543-548.	7.0	82
78	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. Liver International, 2005, 25, 1197-1201.	3.9	35
79	Three Cases of Diffuse Large B-Cell Lymphoma Presenting as Primary Splenic Lymphoma. Yonsei Medical Journal, 2005, 46, 703.	2.2	13
80	Primary liver carcinoma of intermediate (hepatocyte–cholangiocyte) phenotype. Journal of Hepatology, 2004, 40, 298-304.	3.7	199